Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Addex and Merck work on Parkinson's disease candidates; deal ends

Executive Summary

Addex Pharmaceuticals (small-molecule therapeutics for GI and neurological conditions) has teamed up with Merck & Co. and its Merck Sharp & Dohme Research division to discover and develop positive allosteric modulators (PAMs) as potential treatments for Parkinson's disease and possibly for other undisclosed indications.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R+D and Marketing-Licensing

Related Companies